Implantable Cardioverter- Defibrillator Therapy in Clinical Practice

Journal of the American College of Cardiology

Volumn 47, Issue 8, 2006, Pages 1507-1517

  Cesario, David A ^a   Dec, G William ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ION CHANNEL; METOPROLOL; PROCAINAMIDE; SOTALOL;

BRUGADA SYNDROME; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; DEFIBRILLATOR; DISEASE SEVERITY; ELECTROCARDIOGRAM; GENE MUTATION; GENETIC DISORDER; HEART ARREST; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE DYSPLASIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; LONG QT SYNDROME; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SUDDEN DEATH; SURVIVAL RATE; UNITED STATES;

CLINICAL PROTOCOLS; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; HUMANS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS;

EID: 33646023397     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.09.077     Document Type: Review

References (79)

1. Pfeffer M.A., Braunwald E., Moye L.A., et al., The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. N Engl J Med 327 (1992) 669-677
2. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
3. Pitt B., Zannad F., Remme W.J., et al., Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
4. Myerburg R.J. Scientific gaps in the prediction and prevention of sudden cardiac death. J Cardiovasc Electrophysiol 13 (2002) 709-723
5. Zheng Z.J., Croft J.B., Giles W.H., and Mensah G.A. Sudden cardiac death in the United States, 1989 to 1998. Circulation 104 (2001) 2158-2163
6. Cobb L.A., Fahrenbruch C.E., Olsufka M., and Copass M.K. Changing incidence of out-of-hospital ventricular fibrillation, 1980-2000. JAMA 288 (2002) 3008-3013
7. Escobedo L.G., and Zack M.M. Comparison of sudden and nonsudden coronary deaths in the United States. Circulation 93 (1996) 2033-2036
8. Buxton A.E., Lee K.L., Fisher J.D., Josephson M.E., Prystowsky E.N., Hafley G., and Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 341 (1999) 1882-1890
9. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
10. Huikuri H.V., Castellanos A., and Myerburg R.J. Sudden death due to cardiac arrhythmias. N Engl J Med 345 (2001) 1473-1482
11. The MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
12. The Multicentre Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 309 (1983) 331-336
13. Bigger Jr. J.T., Fleiss J.L., Kleiger R., Miller J.P., and Rolnitzky L.M. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 69 (1984) 250-258
14. Luu M., Stevenson W.G., Stevenson L.W., Baron K., and Walden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 80 (1989) 1675-1680
15. Huikuri H.V., Makikallio T.H., Raatikainen P., Perkiomaki J., Castellanos A., and Myerburg R.J. Prediction of sudden cardiac death. Appraisal of the studies and methods assessing the risk of sudden arrhythmic death. Circulation 108 (2003) 110-115
16. The AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators (AVID)-rationale, design, and methods. Am J Cardiol 75 (1995) 470-475
17. Connolly S.J., Gent M., Roberts R.S., et al. Canadian Implantable Defibrillator Study (CIDS). a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101 (2000) 1297-1302
18. Siebels J., Cappato R., Ruppel R., Schneider M.A., Kuck K.H., and CASH Investigators. Preliminary results of the Cardiac Arrest Study Hamburg (CASH). Am J Cardiol 72 (1993) 109F-113F
19. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337 (1997) 1576-1583
20. Chan P.S., and Hayward R.A. Mortality reduction by implantable cardioverter-defibrillators in high-risk patients with heart failure, ischemic heart disease, and new-onset ventricular arrhythmia. an effectiveness study. J Am Coll Cardiol 45 (2005) 1474-1481
21. Oseroff O., Retyk E., and Bochoeyer A. Subanalyses of secondary prevention implantable cardioverter-defibrillator trials. Antiarrhythmics Versus Implantable Defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH). Curr Opin Cardiol 19 (2004) 26-30
22. Moss A.J., Schwartz P.J., Crampton R.S., et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 84 (1991) 1136-1144
23. Schwartz P.J., Moss A.J., Vincent G.M., and Crampton R.S. Diagnostic criteria for the long QT syndrome. An update. Circulation 88 (1993) 782-784
24. Vincent G.M., Timothy K.W., Leppert M., and Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med 327 (1992) 846-852
25. Zareba W., Moss A.J., LeCessie S., et al. Risk of cardiac events in family members of patients with long QT syndrome. J Am Coll Cardiol 26 (1995) 1685-1691
26. Moss A.J., Zareba W., Hall W.J., et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 101 (2000) 616-623
27. Zareba W., Moss A.J., Daubert J.P., Hall W.J., Robinson J.L., and Andrews M. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol 14 (2003) 337-341
28. Zareba W., Moss A.J., Schwartz P.J., et al., International Long-QT Syndrome Registry Research Group. Influence of genotype on the clinical course of the long-QT syndrome. N Engl J Med 339 (1998) 960-965
29. Brugada P., and Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 20 (1992) 1391-1396
30. 3. a marker for sudden death in patients without demonstrable structural heart disease. Circulation 97 (1998) 457-460
31. Priori S.G., Napolitano C., Gasparini M., et al. Natural history of Brugada syndrome. insights for risk stratification and management. Circulation 105 (2002) 1342-1347
32. Maron B.J., Gardin J.M., Flack J.M., Gidding S.S., Kurosaki T.T., and Bild D.E. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92 (1995) 785-789
33. Zou Y., Song L., Wang Z., et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China. a population-based echocardiographic analysis of 8080 adults. Am J Med 116 (2004) 14-18
34. Maron B.J., Mathenge R., Casey S.A., Poliac L.C., and Longe T.F. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol 33 (1999) 1590-1595
35. Maron B.J. Hypertrophic cardiomyopathy. a systematic review. JAMA 287 (2002) 1308-1320
36. Seidman J.G., and Seidman C. The genetic basis for cardiomyopathy. from mutation identification to mechanistic paradigms. Cell 104 (2001) 557-567
37. Komajda M., Charron P., and Tesson F. Genetic aspects of heart failure. Eur J Heart Fail 1 (1999) 121-126
38. Firoozi S., Sharma S., and McKenna W.J. Risk of competitive sport in young athletes with heart disease. Heart 89 (2003) 710-714
39. Spirito P., Bellone P., Harris K.M., Bernabo P., Bruzzi P., and Maron B.J. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342 (2000) 1778-1785
40. Elliott P.M., Poloniecki J., Dickie S., et al. Sudden death in hypertrophic cardiomyopathy. identification of high risk patients. J Am Coll Cardiol 36 (2000) 2212-2218
41. Van Driest S.L., Ackerman M.J., Ommen S.R., et al. Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. Circulation 106 (2002) 3085-3090
42. Ackerman M.J., VanDriest S.L., Ommen S.R., et al. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy. a comprehensive outpatient perspective. J Am Coll Cardiol 39 (2002) 2042-2048
43. Maron B.J., Shen W.K., Link M.S., et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 342 (2000) 365-373
44. Gregoratos G., Abrams J., Epstein A.E., et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 106 (2002) 2145-2161
45. Thiene G., Nava A., Corrado D., Rossi L., and Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med 318 (1988) 129-133
46. McKoy G., Protonotarios N., Crosby A., et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 355 (2000) 2119-2124
47. Alcalai R., Metzger S., Rosenheck S., Meiner V., and Chajek-Shaul T. A recessive mutation in desmoplakin causes arrhythmogenic right ventricular dysplasia, skin disorder, and woolly hair. J Am Coll Cardiol 42 (2003) 319-327
48. Hamid M.S., Norman M., Quraishi A., et al. Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. J Am Coll Cardiol 40 (2002) 1445-1450
49. Nava A., Bauce B., Basso C., et al. Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 36 (2000) 2226-2233
50. Tabib A., Loire R., Chalabreysse L., et al. Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. Circulation 108 (2003) 3000-3005
51. Corrado D., Basso C., Nava A., and Thiene G. Arrhythmogenic right ventricular cardiomyopathy. current diagnostic and management strategies. Cardiol Rev 9 (2001) 259-265
52. Marcus F.I., Fontaine G.H., Guiraudon G., et al. Right ventricular dysplasia. a report of 24 adult cases. Circulation 65 (1982) 384-398
53. Burke A.P., Robinson S., Radentz S., Smialek J., and Virmani R. Sudden death in right ventricular dysplasia with minimal gross abnormalities. J Forensic Sci 44 (1999) 438-443
54. Sen-Chowdhry S., Lowe M.D., Sporton S.C., and McKenna W.J. Arrhythmogenic right ventricular cardiomyopathy. clinical presentation, diagnosis, and management. Am J Med 117 (2004) 685-695
55. Corrado D., Leoni L., Link M.S., et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 108 (2003) 3084-3091
56. Roguin A., Bomma C.S., Nasir K., et al. Implantable cadioverter-defibrillators in patients with right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 43 (2004) 1843-1852
57. Moss A.J., Hall W.J., Cannon D.S., et al., Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 335 (1996) 1933-1940
58. Bigger Jr. J.T., and Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 337 (1997) 1569-1575
59. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
60. Lee D.S., Green L.D., Liu P.P., et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death. a meta-analysis. J Am Coll Cardiol 41 (2003) 1573-1582
61. Hohnloser S.H., Kuck K.H., Dorian P., et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351 (2004) 2481-2488
62. Bansch D., Antz M., Boczor S., et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy. the Cardiomyopathy Trial (CAT). Circulation 105 (2002) 1453-1458
63. Strickberger S.A., Hummel J.D., Bartlett T.G., et al. Amiodarone versus implantable cardioverter-defibrillator. randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol 41 (2003) 1707-1712
64. Fonarow G.C., Feliciano Z., Boyle N.G., et al. Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator. Am J Cardiol 85 (2000) 981-985
65. Grimm W., Hoffmann J.J., Muller H.H., and Maisch B. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. J Am Coll Cardiol 39 (2002) 780-787
66. Knight B.P., Goyal R., Pelosi F., et al. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. J Am Coll Cardiol 33 (1999) 1964-1970
67. Kadish A., Dyer A., Daubert J.P., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 (2004) 2151-2158
68. Sweeney M.O., Ruskin J.N., Garan H., et al. Influence of the implantable cardioverter/defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation. Circulation 92 (1995) 3273-3281
69. Baldasseroni S., Opasich C., Gorini M., et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure. a report from the Italian network on congestive heart failure. Am Heart J 143 (2002) 398-405
70. Aaronson K.D., Schwartz J.S., Chen T.M., Wong K.L., Goin J.E., and Mancini D.M. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95 (1997) 2660-2667
71. Shamim W., Francis D.P., Yousufuddin M., et al. Intraventricular conduction delay. a prognostic marker in chronic heart failure. Int J Cardiol 70 (1999) 171-178
72. Cazeau S., Leclercq C., Lavergne T., et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 344 (2001) 873-880
73. Abraham W.T., Fisher W.G., Smith A.L., et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 346 (2002) 1845-1853
74. Gras D., Leclercq C., Tang A.S., Bucknall C., Luttikhuis H.O., and Kirstein-Pedersen A. Cardiac resynchronization therapy in advanced heart failure. the multicenter InSync clinical study. Eur J Heart Fail 4 (2002) 311-320
75. Bradley D.J., Bradley E.A., Baughman K.L., et al. Cardiac resynchronization and death from progressive heart failure. a meta-analysis of randomized controlled trials. JAMA 289 (2003) 730-740
76. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 (2004) 2140-2150
77. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 (2005) 1539-1549
78. Strickberger A.S., Conti J., Daoud E.G., et al., Council on Clinical Cardiology Subcommittee on Electrocardiography and Arrhythmias and the Quality of Care and Outcomes Research Interdisciplinary Working Group, Heart Rhythm Society. Patient selection for cardiac resynchronization therapy. Circulation 111 (2005) 2146-2150
79. Wilkoff B.L., Cook J.R., Epstein A.E., et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator. the Dual Chamber and VVI Implantable Defibrillator (DAVID) trial. JAMA 288 (2002) 3115-3123